Latest News and Events
Filter by
Selections
November 18, 2025
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Read MoreNovember 4, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
Read MoreOctober 28, 2025
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreOctober 21, 2025
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
Read MoreOctober 7, 2025
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Read MoreSeptember 11, 2025
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
Read MoreSeptember 10, 2025
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Read MoreSeptember 2, 2025